IM Cannabis Corp.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Oren Shuster
- Full Time Employees
- 44
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 3606 – 833 Seymour Street Vancouver BC Canada V6B 0G4
- IPO Date
- May 20, 2020
- CIK
- 0001792030
- Website
- imcannabis.com
- Similar Companies
- Business
- IM Cannabis Corp. is an international medical cannabis company founded in 2008 and headquartered in Canada, operating primarily in Israel and Germany, two of the largest medical cannabis markets. The company produces a range of premium medical cannabis products including dried cannabis flowers, extracts, and other pharmaceutical cannabis formulations, which it sells through its vertically integrated supply chain encompassing breeding, cultivation, importation, distribution, retail pharmacies, online platforms, distribution centers, and logistical hubs. IM Cannabis operates through Israeli subsidiaries such as Focus Medical Herbs Ltd. and owns Adjupharm GmbH in Germany, which distributes medical cannabis to pharmacies. IM Cannabis recently exited its Canadian operations to prioritize sustainable growth in its highest value markets of Israel and Germany. In 2025, it expanded its product portfolio by launching new cannabis brands including the mid-market "Token" and value brand "Mids," alongside established brands such as "Selected" and the ultra-premium Canadian BLKMKT. The company signed a multi-year supply agreement with Canadian LP The Flowr Corporation to import ultra-premium cannabis, enhancing its product offerings. IM Cannabis also announced the acquisition of a 60% stake in an innovative quantum computing bio data company for up to $54 million, marking a strategic diversification into advanced biological data processing technologies. Additionally, IM Cannabis is expanding its retail footprint via acquisitions like Oranim Pharm, one of Jerusalem's leading medical cannabis pharmacies. The company leverages a data-driven ecosystem powered by proprietary patient insights and advanced supply chain management, emphasizing compliance with strict regulatory environments to maintain high product quality and safety standards. IM Cannabis achieved a positive turnaround in early 2025 with improved profitability metrics, including a net profit and significantly enhanced gross margins, reflecting operational efficiencies and a strong market position in the medical cannabis sector. The company's ongoing investments in technology, product innovation, and strategic partnerships aim to strengthen its global brand and commercial presence in the competitive pharmaceutical and biotech industry.
Company News
IM Cannabis Announces Closing of the Sale of IMC Holdings and Its European-Focused Operations, Strengthens Balance Sheet
IM Cannabis Announces Closing of US$1.31 Million Registered Direct Offering of Common Shares
IM Cannabis Regains Compliance with Nasdaq Minimum Bid Price Requirement
IM Cannabis Announces Pricing of US$1.31 Million Registered Direct Offering of Common Shares
IM Cannabis Enters Non-Binding Agreement to Acquire 51% of Space Defense Innovations, Operating in the European Tactical UAS Market
IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing
IM Cannabis Shares Commence Trading on 30:1 Consolidated Basis
IM Cannabis Announces Intention to Complete 30:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance
IM Cannabis Leverages Restructuring Deal to Reduce Financial Strain
IM Cannabis Enters into Agreement to Sell IMC Holdings and European- Focused Assets
IM Cannabis Corp. Announces Second Quarter and First Half 2026 Financial Results
IM Cannabis Raises US$250,000 of Gross Proceeds in Convertible Note Financing
IM Cannabis Provides Corporate Update
IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing
IM Cannabis Corp. Enters into Letter of Intent to Sell its European Activities, Expects to Significantly Reduce Debt by CAD$10.5 million
IM Cannabis Announces Form F-3 Resale Registration Statement Filing
IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing
IM Cannabis Corp. Announces First Quarter 2026 Financial Results
IM Cannabis Raised US$550,000 of Gross Proceeds in Convertible Note Financings
IMC Announces Receipt of Nasdaq Minimum Bid Price Notification